Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
AAPS Selects Certara Vice President of Research and Development Professor Amin Rostami as a Fellow
February 26, 2014
Honor recognizes his advances in predicting in vivo drug responses based on in vitro data
ST. LOUIS, MO – Feb. 26, 2014 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Amin Rostami, Pharm.D., Ph.D., FCP, the company’s vice president of research and development (R&D), has been selected as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in recognition of his professional excellence and contributions to the fields of pharmacokinetics and pharmacology.
AAPS is an international organization which aims to facilitate knowledge exchange between scientists and enhance their contributions to public health.
Professor Rostami’s areas of expertise include pharmacokinetic (PK)-pharmacodynamic (PD) modeling of metabolites, and population PK. He has also directed the research activities of Certara’s Simcyp Consortium, which includes more than 25 international pharmaceutical companies, for more than a decade.
“Amin pioneered the development of user friendly physiologically-based in vitro to in vivo PKPD models, which predict how virtual patient populations will handle a drug,” said AAPS Founder Professor Leslie Benet. “His work is helping to improve clinical trial design, accelerate drug development, and support the regulatory review process.”
These population-based simulations combine demographic, physiological, biochemical and genetic information with drug absorption, metabolism and transport data to determine how a drug will respond in the body.
“By modeling and simulating drug behavior in virtual humans, we have the opportunity to investigate new indications and explore possible drug interactions that might not otherwise be possible,” said Professor Rostami. “AAPS plays a valuable role in educating pharmaceutical scientists and it is an honor not just for me but the whole R&D team within Simcyp and my associate researchers at Manchester Pharmacy School to be recognized in this way.”
Professor Rostami began his career as a Lecturer in Pharmacokinetics in 1987 at Tabriz Pharmacy School, Iran, and he became the first Professor of Systems Pharmacology at the University of Sheffield Medical School, UK, in 2007. In 2009, he was named Chair of Systems Pharmacology at the Centre for Applied Pharmacokinetic Research in the Manchester Pharmacy School, UK.
Professor Rostami has been the author/co-author of more than 145 peer-reviewed articles (with more than 5,500 citations and an h-index of 41). He is currently leading one of the work packages for the Innovative Medicines Initiative ORBITO project to create oral biopharmaceutics tools. He has won several prizes related to his work on in vitro - in vivo extrapolation of PK information.
Professor Rostami has been a member of the grant review board of the Research Council of the Finland Academy of Science, and the Health Research Board in Ireland. He serves on the editorial board of several top pharmacology and drug metabolism journals, including Clinical Pharmacology & Therapeutics, Pharmacometrics and Systems Pharmacology (Associate Editor), Current Drug Metabolism (Associate Editor for Europe), and Biopharmaceutics & Drug Disposition (Associate Editor for Europe).
About Certara
Certara is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com.
Certara Contact:
Diana O’Rourke, 314-951-3310
Director of Marketing
diana.orourke@certara.com
Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com